Keyphrases
Oral Steroids
100%
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Adverse Effects
50%
Long-term Treatment
33%
Remission
33%
Methylprednisolone
33%
University of Minnesota
16%
Minneapolis
16%
Tolerability
16%
Safety Self-efficacy
16%
Sodium
16%
Neuropathy
16%
Intravenous Immunoglobulin (IVIg)
16%
Disability
16%
Older Patients
16%
Immune Cells
16%
Inflammatory Neuropathy
16%
Glucocorticoid-induced Osteoporosis
16%
Immunosuppressive Therapy
16%
Plasma Membrane
16%
Bone Mineral Density
16%
Blood Pressure Changes
16%
Plasma Exchange
16%
Prednisone Therapy
16%
Non-genomic Action
16%
Disease Duration
16%
Arachidonic Acid Release
16%
Serious Adverse Effects
16%
Autoimmune Neuropathy
16%
Disability Evaluation
16%
Low-dose Steroids
16%
Off-treatment
16%
Methylprednisolone Pulse Therapy
16%
Medicine and Dentistry
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Adverse Event
66%
Neuropathy
50%
Methylprednisolone
33%
Disease
16%
Prospective Study
16%
Isotopes of Calcium
16%
Low Drug Dose
16%
Immunoglobulin
16%
Immunity
16%
Blood Pressure
16%
Immunosuppressive Treatment
16%
Immunocompetent Cell
16%
Arachidonic Acid
16%
Bone Density
16%
Plasma Exchange
16%
Weakness
16%
Corticosteroid Induced Osteoporosis
16%
Prednisone
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Adverse Event
66%
Neuropathy
50%
Remission
33%
Methylprednisolone
33%
Tolerability
16%
Prospective Study
16%
Immunoglobulin
16%
Arachidonic Acid
16%
Immunosuppressive Agent
16%
Weakness
16%
Corticosteroid Induced Osteoporosis
16%
Disease
16%
Prednisone
16%